IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action

[1]  R. Bolli.  CAESAR’s legacy: a new era of rigor in preclinical studies of cardioprotection , 2021, Basic Research in Cardiology.

[2]  Z. Giricz,et al.  Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs. , 2021, Journal of visualized experiments : JoVE.

[3]  D. Yellon,et al.  The importance of clinically relevant background therapy in cardioprotective studies , 2020, Basic Research in Cardiology.

[4]  D. Yellon,et al.  Targeting myocardial ischaemic injury in the absence of reperfusion , 2020, Basic Research in Cardiology.

[5]  G. Heusch.  Myocardial ischaemia–reperfusion injury and cardioprotection in perspective , 2020, Nature Reviews Cardiology.

[6]  H. Bøtker,et al.  Improving Translational Research in Sex-specific Effects of Comorbidities and Risk Factors in Ischemic Heart Disease and Cardioprotection: Position Paper and Recommendations of the ESC Working Group on Cellular Biology of the Heart. , 2020, Cardiovascular research.

[7]  M. Ong,et al.  Remote Ischemic Conditioning in Emergency Medicine-Clinical Frontiers and Research Opportunities. , 2020, Shock.

[8]  H. Bøtker,et al.  Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting? , 2020, British journal of pharmacology.

[9]  F. Fernández‐Avilés,et al.  CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions , 2019, Scientific Reports.

[10]  G. Heusch.  Coronary microvascular obstruction: the new frontier in cardioprotection , 2019, Basic Research in Cardiology.

[11]  M. Cour,et al.  Remote ischaemic conditioning: in search of a suitable match , 2019, Nature Reviews Cardiology.

[12]  G. Heusch,et al.  Translating Cardioprotection for Patient Benefit: The EU-CARDIOPROTECTION COST Action. , 2019, Journal of the American College of Cardiology.

[13]  F. Crea,et al.  The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. , 2018, Cardiovascular research.

[14]  Z. Giricz,et al.  Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications , 2018, European heart journal.

[15]  G. Heusch,et al.  Translation, Translation, Translation. , 2018, Circulation research.

[16]  G. Heusch.  Cardioprotection research must leave its comfort zone. , 2018, European heart journal.

[17]  H. Bøtker,et al.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection , 2018, Basic Research in Cardiology.

[18]  E. Ohman,et al.  Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials , 2017, European heart journal.

[19]  C. Held,et al.  Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014 , 2017, European heart journal.

[20]  G. Heusch.  Critical Issues for the Translation of Cardioprotection. , 2017, Circulation research.

[21]  Robert Moreland,et al.  Methodological Rigor in Preclinical Cardiovascular Studies , 2017, Circulation research.

[22]  B. Gersh,et al.  The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. , 2016, European heart journal.

[23]  H. Bøtker,et al.  Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations , 2016, European heart journal.

[24]  Robert Moreland,et al.  Methodological Rigor in Preclinical Cardiovascular Studies: Targets to Enhance Reproducibility and Promote Research Translation , 2017 .

[25]  G. Heusch.  The Coronary Circulation as a Target of Cardioprotection. , 2016, Circulation research.

[26]  E. Ohman,et al.  Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. , 2016, Journal of the American College of Cardiology.

[27]  Steven P Jones,et al.  The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR)Novelty and Significance , 2015 .

[28]  H. Bøtker,et al.  ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies , 2014, Cardiovascular research.

[29]  P. Ferdinandy,et al.  Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning , 2014, Pharmacological Reviews.

[30]  Peter Libby,et al.  Cardiovascular remodelling in coronary artery disease and heart failure , 2014, The Lancet.

[31]  Steven P Jones,et al.  Administration of Sildenafil at Reperfusion Fails to Reduce Infarct Size: Results from the CAESAR Cardioprotection Consortium (LB650) , 2014 .

[32]  Steven P Jones,et al.  Sodium Nitrite Fails to Limit Myocardial Infarct Size: Results from the CAESAR Cardioprotection Consortium (LB645) , 2014 .

[33]  J. Downey,et al.  New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. , 2011, Circulation.

[34]  Roberto Bolli,et al.  Development of an NIH Consortium for PreclinicAl AssESsment of CARdioprotective Therapies (CAESAR): A Paradigm Shift in Studies of Infarct Size Limitation , 2011, Journal of cardiovascular pharmacology and therapeutics.

[35]  G. Heusch,et al.  The in-situ pig heart with regional ischemia/reperfusion - ready for translation. , 2011, Journal of molecular and cellular cardiology.

[36]  J. Curfs,et al.  Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines , 2011, British journal of pharmacology.

[37]  Kay E. Davies,et al.  The ARRIVE guidelines, a welcome improvement to standards for reporting animal research , 2010, The journal of gene medicine.